Leerink Partners Rates MoonLake Immunotherapeutics (MLTX) buy
Leerink Partners maintains its buy rating for MoonLake Immunotherapeutics with a $29 price target, a 48.95% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Leerink Partners rated MoonLake Immunotherapeutics ($MLTX) "buy" with a $29 price target on July 1, 2026.
Since the rating, $MLTX is down 0.3% after 1 week, down 3.6% after 1 month and down 50.1% to date (from the $19.13 close on Jul 1, 2026).
MLTX
MoonLake Immunotherapeutics
Key Points
- Leerink Partners reiterated its buy rating on MoonLake Immunotherapeutics, setting a $29 price target on July 1, 2026.
- Leerink Partners's $29 price target implies 48.95% upside from MoonLake Immunotherapeutics's ($MLTX) current $19.47 share price.
- MoonLake shares were trading at $19.47 on Wednesday, with a market cap of approximately $1.63 billion.
- Several insiders, including CFO Matthias Bodenstedt, executed planned sales in June, while analyst consensus remains positive.
Get $MLTX trade alerts by text
We text you when insiders, Congress or big funds trade $MLTX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated MoonLake Immunotherapeutics alert may contain errors. Disclosures
On July 1, 2026, Leerink Partners reiterated its buy rating on MoonLake Immunotherapeutics, listed on the NasdaqCM under the ticker MLTX. Analyst Thomas Smith set a price target of $29, reflecting confidence in the company's future prospects.
Leerink Partners vs. the S&P 500
Hypothetical returns from Leerink Partners's disclosed trades, not real profit or advice. How we model this.
MoonLake Immunotherapeutics Stock Up 57.1%
Shares of NasdaqCM:MLTX traded near $19.47 on Wednesday. MoonLake Immunotherapeutics, a clinical-stage biotechnology company, has a market cap of about $1.63 billion. The company is not currently profitable, so it has no meaningful P/E ratio. Its stock has seen a 52-week low of $5.95 and a high of $62.75. The 50-day moving average is $18.15, while the 200-day moving average stands at $17.68. The company maintains a strong liquidity position with a current ratio of 8.60 and a quick ratio of 7.89, alongside a debt-to-equity ratio of 39.68.
$MLTX price target
MoonLake Immunotherapeutics daily closes and this analyst's $29 target. Not advice.
Insider Buying and Selling at MoonLake Immunotherapeutics
Recent insider activity at MoonLake Immunotherapeutics included planned sales by Chief Financial Officer Matthias Bodenstedt, who sold 39,120 shares at an average price of $22.04 on June 22, 2026. Earlier in June, Bodenstedt also sold 2,794 shares at $19.60. Meanwhile, on June 17, several insiders, including BVF Partners, executed unplanned purchases, each acquiring 22,195 shares.
Analysts Set New Price Targets
On July 1, 2026, Leerink Partners maintained its buy rating on MoonLake Immunotherapeutics with a $29 price target. This is part of a broader positive analyst sentiment, as Needham also maintained a buy rating with a $30 target on May 12, 2026. HC Wainwright & Co. has been particularly optimistic, setting a $45 target on May 11, 2026. The overall analyst consensus remains a buy, with an average target price of about $27.62 based on 13 analyst opinions.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a biotechnology company based in Zug, Switzerland. It focuses on developing therapies for inflammatory skin and joint diseases. The company is working on Sonelokimab, a novel treatment targeting inflammatory diseases like hidradenitis suppurativa and psoriatic arthritis. Founded in 2021, MoonLake is led by CEO Dr. Jorge Santos da Silva and has about 130 employees.
Bottom Line
Leerink Partners' reiteration of a buy rating for MoonLake Immunotherapeutics reflects strong analyst confidence in the company's growth potential. While the stock has experienced volatility, trading near $19.47, its strong liquidity and innovative pipeline continue to attract interest. Investors should note that analyst ratings are based on historical data and may not reflect current market conditions.
Related Filing Alerts
Source: Leerink Partners's rating change on $MLTX (Jul 1, 2026). Written by software, not financial advice. How we make alerts